Let me explain; the drug reverses liver scars, ballooning, and removes liver fat which would otherwise
lead to definite liver failure. The drug should be in the market yesterday. Liver transplants cost 1 million dollars and they can sell the NASH treatment for 100,000 dollars to 6 million patients that are stage 3, 4
NASH which if left untreated causes cirrhosis or liver failure. I bought some stock in my IRA for the long term at 365.
This is big; that's why the trial was stopped. I would like to buy more but I dont want to concentrate my whole portfolio in one stock. I have seen this happen before with Acorda. Look at their chart for comparison. That went from 2 to 40 and now trades around 30. The FDA should approve this now and save lives and treatment cost. The FDA is slow and some of their employees have been known to take bribes. That's why the FDA is unpredictable.
Good post but what about Europe? They European Union usually moves faster than the FDA. Where are they on EU approval? BTW, Merrill Lynch has this stock as a buy with a PO of $872. I bought an initial position on the opening this morning.
So you are pumping a stock that isnt even through Phase III trials because you were dumb enough to by at $365. The FDA has an approval process and this company is years away from getting through that process. I bet you I can buy this stock in 2016 lower than I can buy it today and thats a fact jack.
Welcome to Biotech rookie.
Since you have followed Accorda, you are somewhat familiar with the FDA process. Right now there is nothing to approve lol. It's not like ICPT has a factory cranking out pills for NASH and all they need is the go ahead from FDA to hit the shelves. ICPT management has said they expect early 2015 approval for Phase III trial, so if you're thinking something will happen sooner than that, I think you are deluding everyone.